Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2
X. Xiao, C. Wang, D. Chang, Y. Wang, X. Dong, T. Jiao, Z. Zhao, L. Ren, C. S. Dela Cruz, L. Sharma, X. Lei, J. Wang
This study identifies 24 FDA-approved compounds that inhibit SARS-CoV-2 replication, with five showing high safety indices and blocking S protein-mediated cell fusion.
Frontiers in Immunology · Nov 25, 2020Peer-reviewedMicrobiology